Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

339 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Chronic oral administration of CI-994: a phase 1 study.
Prakash S, Foster BJ, Meyer M, Wozniak A, Heilbrun LK, Flaherty L, Zalupski M, Radulovic L, Valdivieso M, LoRusso PM. Prakash S, et al. Among authors: lorusso pm. Invest New Drugs. 2001;19(1):1-11. doi: 10.1023/a:1006489328324. Invest New Drugs. 2001. PMID: 11291827 Clinical Trial.
A phase I trial of daily oral 4'- N -benzoyl-staurosporine in combination with protracted continuous infusion 5-fluorouracil in patients with advanced solid malignancies.
Eder JP Jr, Garcia-Carbonero R, Clark JW, Supko JG, Puchalski TA, Ryan DP, Deluca P, Wozniak A, Campbell A, Rothermel J, LoRusso P. Eder JP Jr, et al. Invest New Drugs. 2004 Apr;22(2):139-50. doi: 10.1023/B:DRUG.0000011790.31292.ef. Invest New Drugs. 2004. PMID: 14739662 Clinical Trial.
Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer.
Rinehart J, Adjei AA, Lorusso PM, Waterhouse D, Hecht JR, Natale RB, Hamid O, Varterasian M, Asbury P, Kaldjian EP, Gulyas S, Mitchell DY, Herrera R, Sebolt-Leopold JS, Meyer MB. Rinehart J, et al. Among authors: lorusso pm. J Clin Oncol. 2004 Nov 15;22(22):4456-62. doi: 10.1200/JCO.2004.01.185. Epub 2004 Oct 13. J Clin Oncol. 2004. PMID: 15483017 Clinical Trial.
Phase II trial of fenretinide in advanced renal carcinoma.
Vaishampayan U, Heilbrun LK, Parchment RE, Jain V, Zwiebel J, Boinpally RR, LoRusso P, Hussain M. Vaishampayan U, et al. Invest New Drugs. 2005 Mar;23(2):179-85. doi: 10.1007/s10637-005-5864-7. Invest New Drugs. 2005. PMID: 15744595 Free article. Clinical Trial.
A phase II study of bortezomib in the treatment of metastatic malignant melanoma.
Markovic SN, Geyer SM, Dawkins F, Sharfman W, Albertini M, Maples W, Fracasso PM, Fitch T, Lorusso P, Adjei AA, Erlichman C. Markovic SN, et al. Among authors: lorusso p. Cancer. 2005 Jun 15;103(12):2584-9. doi: 10.1002/cncr.21108. Cancer. 2005. PMID: 15887220 Free article. Clinical Trial.
A phase I study of flavopiridol and docetaxel.
El-Rayes BF, Gadgeel S, Parchment R, Lorusso P, Philip PA. El-Rayes BF, et al. Invest New Drugs. 2006 Jul;24(4):305-10. doi: 10.1007/s10637-005-4343-5. Invest New Drugs. 2006. PMID: 16683073 Clinical Trial.
A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors.
Heath EI, Bible K, Martell RE, Adelman DC, Lorusso PM. Heath EI, et al. Among authors: lorusso pm. Invest New Drugs. 2008 Feb;26(1):59-65. doi: 10.1007/s10637-007-9090-3. Epub 2007 Oct 16. Invest New Drugs. 2008. PMID: 17938863 Clinical Trial.
339 results